---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Definition and etiology"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Definition and etiology. Topics: Hormone receptor-positive and HER2-positive tumor definitions, Estrogen receptor-positive threshold: ASCO/CAP guideline, HER2 status: ASCO/CAP guideline, Intrinsic subtypes and their hormone receptor surrogates, and 7 further topics. 11 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Hormone receptor-positive and HER2-positive tumor definitions

> “HR+ means that tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors.”
> “HER2+ means that tumor cells make high levels of a protein called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.1-2"></a>

### Estrogen receptor-positive threshold: ASCO/CAP guideline

> “Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.”
> “However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive.”
> “Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.”
> “A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.”

Source: [Allison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928404/)

<a id="topic-2.2.1.1-3"></a>

### HER2 status: ASCO/CAP guideline

> “The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.”
> “This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.”

Source: [Wolff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37284804/)

<a id="topic-2.2.1.1-4"></a>

### Intrinsic subtypes and their hormone receptor surrogates

> “Four out of five breast cancers test positive for hormone (estrogen and/or progesterone) receptors (HR+) and are generally classified as either Luminal A (70%) or Luminal B (9%) based on the presence of HER2/ERBB2.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-5"></a>

### Advanced breast cancer: international consensus definition

> “In the ABC guidelines, advanced breast cancer is defined as comprising both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC), which includes both distant recurrent disease and stage IV at diagnosis”
> “Advanced/metastatic breast cancer is still an incurable disease for the vast majority of patients.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.1-6"></a>

### Distant stage and stage IV classification

> “distant stage, cancer that has spread to distant organs and/or lymph nodes, including nodes above the collarbone.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

> “If a patient presents with M1 disease before receiving neoadjuvant systemic therapy, the stage is Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

<a id="topic-2.2.1.1-7"></a>

### De novo and recurrent metastatic disease

> “Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.1-8"></a>

### Previously treated disease: endocrine resistance definitions

> “Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.”
> “Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.”
> “The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.”
> “The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.1-9"></a>

### Risk factors: U.S. summary

> “Most women who develop breast cancer have no known risk factors. Approximately 30% of cases can be attributed to potentially modifiable risk factors, such as excess body weight (postmenopausal breast cancer), physical inactivity, and alcohol consumption.”
> “The strongest risk factors are a personal or family history of breast cancer or a personal history of lesions associated with risk (e.g., DCIS, proliferative lesions with atypia); high-dose radiation to the chest; or certain inherited genetic variations (e.g., BRCA1 or BRCA2 gene mutations).”
> “Genetic variations in BRCA1 and BRCA2 account for 5% to 10% of all female breast cancers and 15% to 20% of familial breast cancers.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-10"></a>

### Risk factors: hormone receptor-positive disease and reproductive history

> “Risk increases immediately following childbirth, but decreases for hormone-receptor positive disease after two decades, with an additional reduction among women who are young at first childbirth and/or have more children.”
> “Note: Relative risk for some factors vary by breast cancer molecular subtype.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-11"></a>

### Risk factors: NCI health professional summary

> “Increasing age is the most important risk factor for most cancers.”
> “Of all women with breast cancer, 5% to 10% may have a germline pathogenic variant in the BRCA1 and BRCA2 genes.”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
